Joshua Resnick - 07 Jan 2026 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Reporting relationship: Director
Issuer ticker: CDTX
Reported as of: 07 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jan 2026, 20:20:45 UTC
Prior SEC filing: 18 Jun 2025
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Shane Ward, Attorney-in-Fact

Key filing fact

Joshua Resnick filed Form 4 for Cidara Therapeutics, Inc. (CDTX) on 07 Jan 2026.

Key facts

This page summarizes Joshua Resnick's Form 4 filing for Cidara Therapeutics, Inc. (CDTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Jan 2026, 20:20.

Change

Previous filing in this sequence was filed on 18 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001690959 Primary reporting owner

Resnick Joshua

Relationship: Director
Address: C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO
Signature: /s/ Shane Ward, Attorney-in-Fact
Signature date: 07 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CDTX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -22,200
Change %: -100%
Price
Shares after: 0
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,200
Exercise price: $26.62
Footnotes: F1, F2, F3

CDTX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -5,079
Change %: -100%
Price
Shares after: 0
Date: 07 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,079
Exercise price: $21.31
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Joshua Resnick is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger").

Footnote F2

As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.

Footnote F3

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.